Bifidobacterium animalis subsp. lactis V9 overcomes CYFRA 21-1–linked immunochemotherapy resistance in NSCLC via microbial metabolites
Science Advances · 2026
DOI: 10.1126/sciadv.aeg8202 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Science Advances, 2026. Verfasst von Cuijiao Feng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural University, Hohhot, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Bifidobacterium animalis, Antigens, Neoplasm. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Earmarked fund.
Abstract (Originalsprache)
Gut dysbiosis drives therapeutic resistance, yet the relationships among typical tumor markers, gut microbiota, and treatment efficacy remain poorly defined. Here, elevated serum CYFRA 21-1 in advanced non–small cell lung cancer (NSCLC) correlates with gut dysbiosis, including Bifidobacterium animalis depletion and reduced immunomodulatory metabolites. Fecal supernatant from patients with high-CYFRA attenuated immunochemotherapy efficacy in tumor-bearing mice, linked to disrupted tryptophan and phenylalanine metabolism. Adjuvant B. animalis subsp. lactis V9 enhanced tumor control and antitumor immunity, coinciding with elevated quinaldic acid and catechol, metabolites associated with caspase-dependent apoptosis and ferroptosis. Cell-free fecal supernatant transferred antitumor effects, independent of bacterial colonization. In a randomized, double-blind, placebo-controlled pilot trial ( n = 30), adjunctive B. lactis V9 associated with a higher objective response rate (47% versus 33%), disease control rate (87% versus 67%), and prolonged progression-free survival in responders, who exhibited enriched B. animalis and elevated quinaldic acid/catechol (area under the curve = 0.73/0.82). These findings suggest CYFRA 21-1 may identify a modifiable, microbiome-linked state of treatment resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural University, Hohhot, China.
- Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs, Inner Mongolia Agricultural University, Hohhot, China.
- Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, China.
- Medical Oncology, Inner Mongolia People's Hospital, Hohhot, China.
ORCID-Profile: Cuijiao Feng, Li Dong, Zhihong Sun, Heping Zhang
Förderung
- National Natural Science Foundation of China
- Earmarked fund
Zitieren
APA
Feng, C., Gao, G., He, Q., Kwok, L. Y., Liu, C., Li, C., Dong, L., Sun, Z., & Zhang, H. (2026). Bifidobacterium animalis subsp. lactis V9 overcomes CYFRA 21-1–linked immunochemotherapy resistance in NSCLC via microbial metabolites. Science Advances. https://doi.org/10.1126/sciadv.aeg8202
Vancouver
Feng C, Gao G, He Q, Kwok LY, Liu C, Li C, et al. Bifidobacterium animalis subsp. lactis V9 overcomes CYFRA 21-1–linked immunochemotherapy resistance in NSCLC via microbial metabolites. Science Advances. 2026. doi:10.1126/sciadv.aeg8202
BibTeX
@article{Feng2026,
author = {Feng, Cuijiao and Gao, Guangqi and He, Qiuwen and Kwok, Lai-Yu and Liu, Cong and Li, Chang and Dong, Li and Sun, Zhihong and Zhang, Heping},
title = {Bifidobacterium animalis subsp. lactis V9 overcomes CYFRA 21-1–linked immunochemotherapy resistance in NSCLC via microbial metabolites},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aeg8202}
}
EUVIMED